The fine and specialty chemicals business: how it really works

By the end you will be able to

• Distinguish commodities, fine chemicals and specialty chemicals using Pollak's criteria and size estimates
• Describe the equipment, capacity and cost structure of a multipurpose batch plant
• Calculate conversion cost per kilogram from operating cost, utilisation and volume-time-output
• Trace a custom manufacturing project from inquiry to validated commercial supply, with its timelines and regulatory steps
• Explain how exclusive and generic APIs are priced and why patent expiry collapses prices
• Assess why profits swing with capacity utilisation and why production has shifted to India and China

Contents

1. Part 1 Where fine chemicals sit in the chemical universe

   The dye makers of the last module were the first firms to live by multistep batch synthesis of complex molecules sold to a few expert buyers. Their heirs are today's fine chemical companies. Before looking at how they work, we need clear boundaries: what separates a fine chemical from a commodity on one side and a specialty on the other, and how much money sits in each tier.

   • Fine chemicals are sold for what they are; specialties are sold for what they do
   • Following one drug up the value chain shows where value is added
   • Fine chemicals are about a $85 billion slice, and most of it is made in-house
2. Part 2 Products, customers and the chemist's toolbox

   Fine chemical companies sell four layers of product to a small, concentrated set of customers, mostly drug makers. The chemistry they use is broad but largely standard; competitive edges come from a few hard reactions, from chirality and from biology. This part sets out what is made, for whom, and with which tools, including where biotechnology changes the economics.

   • Four layers of product serve a few large, risk-averse customers
   • Most of the chemistry runs in standard kit; the edge lies in a few hard reactions
   • Biotechnology cuts steps and cost, but big molecules are a different business
3. Part 3 Inside the multipurpose batch plant

   The physical heart of the business is a building full of stirred vessels of a few cubic metres each, reconfigured for a new product every few weeks. Understanding why it looks like this, what it costs, and how its cost is turned into a price per kilogram explains most of the industry's economics, including its obsession with keeping reactors busy.

   • Small volumes and short product lives make the multipurpose plant the norm
   • A cGMP multipurpose plant costs close to $1 million per cubic metre
   • Raw materials are about a third of cost; most of the rest is the cost of owning the plant
   • Conversion cost is priced per cubic metre-hour, so idle time is the enemy
4. Part 4 Business models and how deals are made

   The same reactors serve very different businesses. Making an exclusive intermediate for one patented drug is a project sold on trust and project management; making an API for generics is a product sold on price. This part explains the models, follows a custom manufacturing project from inquiry to commercial supply, and shows how prices, contracts and patent expiries shape returns.

   • Custom manufacturing and API-for-generics share plants but are different businesses
   • From first inquiry to commercial supply takes one to two years of project work
   • Prices are built bottom-up for exclusives and top-down for generics
   • Patent expiry turns a drug into a price war within a year
5. Part 5 Industry structure, cycles and the shift east

   Thousands of firms, none dominant, sell to a few powerful buyers from plants whose costs are mostly fixed. That combination produces fierce cycles, a history of overpriced acquisitions, and a steady move of manufacturing to India and China. This part looks at structure, profits, globalisation, and Pollak's view of what separates the winners.

   • A fragmented industry where size brings little advantage
   • Because costs are fixed, capacity utilisation swings profits by a factor of two
   • India and China win on cost and generics; the West keeps the exclusive end
   • R&D is mostly development, marketing is mostly relationships, and the winners are midsized specialists
6. Wrap-up Key terms, try it in the table, final quiz, sources